Jack Yongfeng Zhang compensation by year
Amphastar Pharmaceuticals Summary Compensation Table · all 7 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $880,000 | $1,091,539 | $897,585 | $898,000 | $898,000 | $1,113,866 | $950,911 |
| Bonus | $296,154 | $338,462 | $393,739 | $394,000 | $310,847 | $293,578 | $329,747 |
| Stock awards | $2,089,996 | $1,939,994 | $1,990,018 | $1,989,994 | $2,288,490 | $2,671,992 | $3,301,981 |
| Option awards | $2,090,004 | $1,940,009 | $1,989,985 | $1,990,009 | $2,288,518 | $2,672,017 | $3,302,024 |
| Non-equity incentive | $372,300 | $549,869 | $680,900 | $657,520 | $673,000 | $670,000 | $361,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | — |
| All other | $27,078 | $14,834 | $17,515 | $33,426 | $50,565 | $56,498 | $63,687 |
| Total | $5,755,532 | $5,874,707 | $5,969,742 | $5,962,949 | $6,509,420 | $7,477,951 | $8,309,350 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amphastar Pharmaceuticals, Inc. DEF 14A filed April 13, 2026, accession 0001297184-26-000023, and prior-year filings.
How this page was built: the Amphastar Pharmaceuticals, Inc. filed document, accession 0001297184-26-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 116,226 | $3,112,532 | — |
| RSU | 48,232 | $1,291,653 | — |
| RSU | 40,691 | $1,089,705 | — |
| RSU | 19,228 | $514,926 | — |
| Option | 246,821 | — | $28.41 |
| Option | 44,365 | — | $34.74 |
| Option | 85,744 | — | $35.13 |
| Option | 101,604 | — | $46.68 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Amphastar Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Amphastar Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jack Yongfeng Zhang · this page | Chief Executive Officer, President, Chief Scientific Officer and Director | $8,309,350 |
| Mary Ziping Luo | Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors | $4,031,078 |
| William Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | $3,238,682 |
| Rong Zhou | Senior Executive Vice President of Production Center; Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd. | $2,542,634 |
| Jacob Liawatidewi | Executive Vice President of Sales and Marketing and Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S., Corporate Secretary and Director | $2,037,856 |
Board service
Amphastar Pharmaceuticals board · FY2021–FY2025How this board is paid
Company policy: Amphastar Pharmaceuticals pays directors a $55,000 cash retainer and $260,000 in equity. As stated in Amphastar Pharmaceuticals's FY2025 proxy.
The full Amphastar Pharmaceuticals compensation record
free company briefThis page is one person within Amphastar Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Amphastar Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Amphastar Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amphastar Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.